Key result
Immunomimetic designer cells achieved a 100% cure rate of acute MRSA infections in mice, whereas conventional vancomycin treatment failed.
Why the study?
Do immunomimetic designer cells improve cure rates of acute MRSA infections in mice compared to conventional vancomycin?
Do immunomimetic designer cells improve cure rates of acute MRSA infections in mice compared to conventional vancomycin?
Immunomimetic designer cells engineered to autonomously detect and destroy MRSA achieved a 100% cure rate in a mouse model of acute infection, outperforming conventional vancomycin.
Answers are grounded in this paper and cite their sources.
Engineered cells may enable autonomous infection control; leaves open clinical translation and safety validation.
Many community- and hospital-acquired bacterial infections are caused by antibiotic-resistant pathogens. Methicillin-resistant Staphylococcus aureus (MRSA) predisposes humans to invasive infections that are difficult to eradicate. We designed a closed-loop gene network programming mammalian cells to autonomously detect and eliminate bacterial infections. The genetic circuit contains human Toll-like receptors as the bacterial sensor and a synthetic promoter driving reversible and adjustable expression of lysostaphin, a bacteriolytic enzyme highly lethal to S. aureus. Immunomimetic designer cells harboring this genetic circuit exhibited fast and robust sense-and-destroy kinetics against live staphylococci. When tested in a foreign-body infection model in mice, microencapsulated cell implants prevented planktonic MRSA infection and reduced MRSA biofilm formation by 91%. Notably, this system achieved a 100% cure rate of acute MRSA infections, whereas conventional vancomycin treatment failed. These results suggest that immunomimetic designer cells could offer a therapeutic approach for early detection, prevention, and cure of pathogenic infections in the post-antibiotic era.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2018) studied MRSA infection. Immunomimetic designer cells vs. Conventional vancomycin treatment was evaluated on Cure rate of acute MRSA infections. Immunomimetic designer cells achieved a 100% cure rate of acute MRSA infections in mice, whereas conventional vancomycin treatment failed.
Synapse has enriched 10 related papers. Consider them for comparative context: